| Menopause |
1 |
1 |
| Hormonal Therapy |
0 |
0.99 |
| Breast Cancer |
0 |
0.45 |
| Cancer |
0 |
0.4 |
| Virginia |
0 |
0.4 |
| Biologic Therapy |
0 |
0.98 |
| Thromboembolism |
0 |
0.32 |
| Cardiovascular Risk Management |
0 |
0.3 |
| Breast |
0 |
0.27 |
| Cardiovascular disease |
0 |
0.27 |
| Cerebrovascular Accident |
0 |
0.27 |
| Electronic Health Record (EHR) |
0 |
0.16 |
| Deep Venous Thrombosis |
0 |
0.14 |
| Adverse Effects |
0 |
0.13 |
| Allergy |
0 |
0.13 |
| Biosimilars |
0 |
0.13 |
| Board Certification |
0 |
0.13 |
| Electronic Medical Record |
0 |
0.13 |
| Generics |
0 |
0.13 |
| Heart |
0 |
0.13 |
| Insurance |
0 |
0.13 |
| Residency |
0 |
0.13 |
| Students |
0 |
0.13 |
| Testosterone |
0 |
0.13 |
| Texas |
0 |
0.13 |
| Thrombosis |
0 |
0.13 |
| Vein |
0 |
0.13 |
| Alzheimer Disease |
0 |
0.1 |
| Patient Safety |
0 |
0.1 |
| Revenue and Practice Management |
0 |
0.1 |